PT - JOURNAL ARTICLE AU - Issam Bennis TI - COVID-19 case management: The policy model in Morocco context AID - 10.1101/2020.11.07.20227603 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.07.20227603 4099 - http://medrxiv.org/content/early/2020/11/10/2020.11.07.20227603.short 4100 - http://medrxiv.org/content/early/2020/11/10/2020.11.07.20227603.full AB - Background Based on the updated scientific evidence around SARS-CoV-2 diagnostic, health policymakers had to consider that many decisions could enhance or limit the success of the overall COVID-19 control strategy. The purpose of this study is to share alternative COVID-19 case management based on the updated international knowledge.Methods This study presents the main information about COVID-19 case management in Morocco from March to October 2020. The NVivo qualitative model content analysis was used to compare and prioritize health decisions with updated scientific evidence.Results The lack of molecular diagnostic accuracy using the interpretation of cycles quantification values, was targeted only by allowing all private laboratories to do RT qPCR. However, there is an urgent need for standardisation with accurate molecular SARS-CoV-2 thermocyclers and kits that notify systematic cycles quantification and do more tests per days to control the spread effectively. A predictive tree of the cycle’s range is presented following three steps: 1) the initial clinical definition, 2) the molecular confirmation, 3) and the diagnostic follows up results of the RT qPCR up to 28 days after the onset. At the same time, the seasonal vaccination against influenza and pneumonia could help to reduce COVID-19 deaths.Conclusions Until an available SARS-CoV-2 specific vaccine and/or curative effective treatment, updated control strategy in Morocco and similar context countries require to target population living in highly COVID-19 epidemic cities or areas by mass testing with the right interpretation of PCR values changes, associated to seasonal vaccination to foster the immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding source supported the studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper does not contain any studies done by the authors involving human participants. It is based on a review of the literature and public statistical available data updated each day by the Moroccan Ministry of Health and available by the website link: http://www.covidmaroc.maAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analysed during the current study are available from the corresponding author on reasonable request.COVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2PCRPolymerase chain reactionRT-qPCRReal-time quantitative PCRRNARibonucleic acidDNADeoxy-ribonucleic acidMoHMinistry of HealthIgG/IgMImmunoglobulin G/ Immunoglobulin MPoCPoint of careELISAEnzyme-linked immunosorbent assayUSAUnited States of AmericaLoDLimit of DetectionCqCycles quantification valueCTChest tomographyBCGBacillus Calmette–Guérin